About: Polatuzumab vedotin

Property	Value
dbo:abstract	Polatuzumab vedotin (INN; brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab after at least two prior therapies. The drug was developed by Genentech (subsidiary of Roche). (en) Polatuzumab vedotine (merknaam Polivy) is een cytostaticum gekoppeld aan een monoklonaal antilichaam gericht tegen . Het middel is ontwikkeld door Genentech en Roche. Het middel wordt sinds 2020 ingezet tegen het diffuus grootcellig B-cellymfoom en folliculair lymfoom, en soms bij andere laaggradige lymfomen. (nl) ポラツズマブベドチン（Polatuzumab vedotin）は、がん治療用に設計された抗体薬物複合体（ADC）である。米国食品医薬品局は2019年6月、ベンダムスチンおよびリツキシマブとの併用によるびまん性大細胞型B細胞リンパ腫（DLBCL）の治療薬としてポラツズマブベドチンを承認した。日本では2021年3月に再発または難治性のDLBCLに対して承認され、同年12月には未治療のDLBCLに対する適応拡大が申請された。 (ja) Полатузумаб ведотин — конъюгат антитело-препарат для лечения диффузной B-крупноклеточной лимфомы. Одобрен для применения: США (2019). (ru)
dbo:alternativeName	Polivy (en)
dbo:casNumber	1313206-42-6
dbo:drugbank	DB12240
dbo:fdaUniiCode	KG6VO684Z6
dbo:kegg	D10761
dbo:medlinePlus	a619039
dbo:wikiPageExternalLink	https://druginfo.nlm.nih.gov/drugportal/name/polatuzumab%20vedotin https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761121Orig1s000TOC.cfm
dbo:wikiPageID	46655721 (xsd:integer)
dbo:wikiPageLength	9435 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1124055378 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Priority_review dbr:Bendamustine dbr:Antibody-drug_conjugate dbr:Hoffmann-La_Roche dbr:Rituximab dbc:Antibody-drug_conjugates dbr:Orphan_drug dbr:Genentech dbr:Committee_for_Medicinal_Products_for_Human_Use dbc:Genentech_brands dbc:Orphan_drugs dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbr:International_Nonproprietary_Name dbc:Breakthrough_therapy dbc:Monoclonal_antibodies_for_tumors dbc:Hoffmann-La_Roche_brands dbr:CD79B dbr:R-CHOP dbr:Large_B-cell_lymphoma
dbp:atcPrefix	L01 (en)
dbp:atcSuffix	FX14 (en)
dbp:c	6670 (xsd:integer)
dbp:casNumber	1313206 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:dailymedid	Polatuzumab_vedotin (en)
dbp:drugbank	DB12240 (en)
dbp:h	10317 (xsd:integer)
dbp:iupharLigand	8404 (xsd:integer)
dbp:kegg	D10761 (en)
dbp:legalAu	S4 (en)
dbp:legalCa	Rx-only / Schedule D (en)
dbp:legalEu	Rx-only (en)
dbp:legalStatus	Rx-only (en)
dbp:legalUs	Rx-only (en)
dbp:licenceEu	yes (en)
dbp:licenceUs	Polivy (en)
dbp:mabType	mab (en)
dbp:medlineplus	a619039 (en)
dbp:n	1745 (xsd:integer)
dbp:o	2087 (xsd:integer)
dbp:pregnancyAu	D (en)
dbp:pubchemsubstance	347911301 (xsd:integer)
dbp:s	40 (xsd:integer)
dbp:source	zu/o (en)
dbp:synonyms	DCDS4501A, RG7596, polatuzumab vedotin-piiq (en)
dbp:target	dbr:CD79B
dbp:tradename	Polivy (en)
dbp:type	mab (en)
dbp:unii	KG6VO684Z6 (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Keggcite dbt:Drugs.com dbt:Monoclonals_for_tumors
dcterms:subject	dbc:Antibody-drug_conjugates dbc:Genentech_brands dbc:Orphan_drugs dbc:Breakthrough_therapy dbc:Monoclonal_antibodies_for_tumors dbc:Hoffmann-La_Roche_brands
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Polatuzumab vedotin (INN; brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab after at least two prior therapies. The drug was developed by Genentech (subsidiary of Roche). (en) Polatuzumab vedotine (merknaam Polivy) is een cytostaticum gekoppeld aan een monoklonaal antilichaam gericht tegen . Het middel is ontwikkeld door Genentech en Roche. Het middel wordt sinds 2020 ingezet tegen het diffuus grootcellig B-cellymfoom en folliculair lymfoom, en soms bij andere laaggradige lymfomen. (nl) ポラツズマブベドチン（Polatuzumab vedotin）は、がん治療用に設計された抗体薬物複合体（ADC）である。米国食品医薬品局は2019年6月、ベンダムスチンおよびリツキシマブとの併用によるびまん性大細胞型B細胞リンパ腫（DLBCL）の治療薬としてポラツズマブベドチンを承認した。日本では2021年3月に再発または難治性のDLBCLに対して承認され、同年12月には未治療のDLBCLに対する適応拡大が申請された。 (ja) Полатузумаб ведотин — конъюгат антитело-препарат для лечения диффузной B-крупноклеточной лимфомы. Одобрен для применения: США (2019). (ru)
rdfs:label	ポラツズマブベドチン (ja) Polatuzumab vedotin (en) Polatuzumab vedotine (nl) Полатузумаб ведотин (ru)
owl:sameAs	freebase:Polatuzumab vedotin yago-res:Polatuzumab vedotin wikidata:Polatuzumab vedotin dbpedia-ja:Polatuzumab vedotin dbpedia-nl:Polatuzumab vedotin dbpedia-ru:Polatuzumab vedotin https://global.dbpedia.org/id/uWnt
prov:wasDerivedFrom	wikipedia-en:Polatuzumab_vedotin?oldid=1124055378&ns=0
foaf:homepage	http://U.S.
foaf:isPrimaryTopicOf	wikipedia-en:Polatuzumab_vedotin
is dbo:product of	dbr:Genentech
is dbo:wikiPageRedirects of	dbr:Polivy dbr:Polatuzumab_vedotin-piiq dbr:RG7596
is dbo:wikiPageWikiLink of	dbr:Roche dbr:Antibody-drug_conjugate dbr:Genentech dbr:Monomethyl_auristatin_E dbr:Monoclonal_antibody_therapy dbr:Richter's_transformation dbr:ATC_code_L01 dbr:Diffuse_large_B-cell_lymphoma dbr:List_of_therapeutic_monoclonal_antibodies dbr:Polivy dbr:Polatuzumab_vedotin-piiq dbr:RG7596
is foaf:primaryTopic of	wikipedia-en:Polatuzumab_vedotin